Interpretation
ALCOHOL-RELATED LIVER DISEASE, LIVER FIBROSIS
In patients with alcohol-related liver disease, rifaximin-α might reduce progression of liver fibrosis. These findings warrant confirmation in a multicentre phase 3 trial.